Companies: 10,795·Total market cap: $144.5T
ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

PRQRNASDAQHealthcare● Active
$1.53
+$0.03(+2.00%)
Market Cap$161202330
P/E Ratio—
52W High$3.1
52W Low$1.33
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

ProQR Therapeutics N.V. (PRQR) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · PRQR · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.44prqr eps ttm · prqr earnings per shareEarnings history
PE Ratio (TTM)—prqr pe ratio ttm · prqr price to earningsPE Ratio deep dive
Revenue (TTM)$13.4Mprqr revenue ttm · prqr annual revenueFull revenue history
Dividend YieldNo Dividenddoes prqr pay dividends · prqr dividend yieldDividend history
Shares Outstanding105.3Mprqr shares outstanding · prqr floatShares outstanding history
Next EarningsAug 6, 2026Est.prqr earnings date · prqr next earningsEarnings history

Explore ProQR Therapeutics N.V. Data

prqr stock data · financials
Market Cap$161.2Mprqr market cap · prqr valuation
Analyst Forecast$4 · Buy
DividendsNo Dividenddoes proqr therapeutics n.v. pay dividends · prqr dividend yield
Revenue$15.3M-19.18%proqr therapeutics n.v. annual revenue · prqr revenue
EarningsEPS $-0.38-11.76%prqr earnings · prqr eps
PE Ratio—prqr pe ratio · prqr price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$15.3M▼ 19.18% YoY
202320242025
proqr therapeutics n.v. revenue · prqr revenue 2025
FY 2025Net Income-$40.5M▼ 45.95% YoY
202320242025
proqr therapeutics n.v. net income · prqr profit 2025
FY 2025EPS$-0.38▼ 11.76% YoY
202320242025
prqr eps · proqr therapeutics n.v. earnings per share 2025
TTM:Revenue: $13.4MNet Income: -$45.6MEPS: $-0.44View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy10 analystsis prqr a buy · prqr analyst rating
Strong Buy
1
Buy
8
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$2.00Low
$1.53Current
$3.63Avg Target137.25% upside
$5.00High
prqr price target · prqr 12 month forecast

Total: 10 · Buy rate: 90.0%

The PRQR analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $3.63, representing +137.25% upside from the current price of $1.53.

Stock Performance

Full History
1D+2.00%
1W+4.08%
1M-3.16%
3M-14.04%
YTD-24.26%
1Y-16.39%
5Y-76.78%

About ProQR Therapeutics N.V.

CEODaniel Anton de Boer
IPO DateSep 18, 2014
Employees166
CountryNL
Websiteproqr.com

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes tw…

BiotechnologyHealthcareNASDAQNL

what is proqr therapeutics n.v. · prqr stock overview · proqr therapeutics n.v. company profile · who is proqr therapeutics n.v. ceo · prqr NASDAQ · proqr therapeutics n.v. headquarters · proqr therapeutics n.v. business segments

About Stock Overview & Key Data

ProQR Therapeutics N.V. (PRQR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 18, 2014. As of the latest trading session, PRQR stock price is $1.53, with a market capitalization of $161.2M. The stock has returned -16.39% over the past 12 months and -24.26% year-to-date.

According to 10 Wall Street analysts, the consensus rating for ProQR Therapeutics N.V. stock is Buy, with an average 12-month price target of $3.63. In fiscal year 2025, ProQR Therapeutics N.V. reported revenue of $15.3M and net income of -$40.5M. For detailed data — including ProQR Therapeutics N.V. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, ProQR Therapeutics N.V. (PRQR) stock price is $1.53. The stock is traded on NASDAQ under the ticker symbol PRQR. The 52-week range is $1.33 – $3.10.

PRQR stock pricePRQR quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice